Scandinavian ChemoTech and the India-Sweden Healthcare Innovation Centre celebrate the start of the clinical trial at AIIMS Jodhpur
Last week managers from both ChemoTech, the India-Sweden Healthcare Innovation Centre and Business Sweden were present during the official opening of the TSE Trial at All India Institute of Medical Sciences (AIIMS) in Jodhpur.
The Investigator Initiated Trial that today officially was opened, at AIIMS Jodhpur, is designed to collect data from 30 patients with Head & Neck (H&N) cancer. The trial’s primary endpoint is to document the overall tumour control, after TSE therapy, in difficult-to-treat advanced H&N cancer patients. An even more important endpoint of the trial is to explore the immune system’s response to TSE. The trial includes extensive biomarker studies to help design further studies on the usage of TSE in combination with other therapies, especially immunotherapy.
“I congratulate Prof. Dr Jeevan Vishnoi and the research teams at AIIMS Jodhpur for initiating the TSE clinical trial for H&N cancer patients. Apart from the clinical outcomes, the study attempts to look at the tumour microenvironment modulation by TSE and its potential role in the curative lines of treatment for solid tumours.” - says Dr Suhail Mufti, Medical Adviser at Scandinavian ChemoTech
“It is an immense pleasure to announce that we have formally started the investigator-initiated trial for TSE in H&N cancer. H&N cancers in India are a major public health problem. The trial looks at the standardization of treatment guidelines so that TSE can be easily used in multiple centres across the country. Our team is also looking at various immunological biomarkers to further understand the immune modulation potential of TSE which could suggest TSE-based combinatorial and personalized treatment approaches.” - says Dr Jeewan Ram Vishnoi, Robotic & Laparoscopic Onco-Surgeon and Associate Professor of Surgical Oncology at AIIMS Jodhpur
“Business Sweden and India-Sweden Healthcare Innovation Centre are very happy to be an active part of creating this bilateral venture in cancer research along with technology partner ChemoTech from Sweden at AIIMS Jodhpur. It was an honour for me to be part of the official opening which was yet another milestone that could potentially change outcomes for thousands of patients in India and other parts of the world.” - says Cecilia Oskarsson, The Swedish Trade Commissioner in India and Head of Business Sweden
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
ir@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
